Talley N J, Locke G R, Lahr B D, Zinsmeister A R, Cohard-Radice M, D'Elia T V, Tack J, Earnest D L
Clinical Enteric Neuroscience, Translational and Epidemiological Research Program (CENTER), Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Aliment Pharmacol Ther. 2006 Apr 1;23(7):923-36. doi: 10.1111/j.1365-2036.2006.02845.x.
BACKGROUND: Trials in functional dyspepsia report placebo response rates of 30% to 40%. AIM: We aimed to identify predictors of the placebo response. METHODS: Patients from primary, secondary and tertiary practices with functional dyspepsia defined by Rome II criteria were enrolled into one of four clinical trials; 220 patients were randomized to receive placebo. Scintigraphic assessment of gastric emptying at baseline was repeated at the end of the treatment in those with delayed emptying. After a 2 week run-in period, patients were followed for 8 weeks on placebo. Response was assessed on a weekly basis and a responder was defined as satisfactory relief of meal-related symptoms on at least 50% of weeks. RESULTS: The mean age was 44 years (range 18-82) and 74% were female; 76 (35%) were placebo responders. The predominant symptom was an unstable measure over the trial. Independent predictors of a lower placebo response were lower body mass index and a more consistent predominant symptom pattern (both P < 0.05). No association was seen with age, gender, centre type, baseline symptom score, baseline or change in gastric emptying, or baseline quality of life. CONCLUSION: In functional dyspepsia, a consistent predominant symptom pattern and lower body mass index may be associated with a lower placebo response rate.
Aliment Pharmacol Ther. 2006-4-1
Neurogastroenterol Motil. 2009-3
Clin Gastroenterol Hepatol. 2008-7
Neurogastroenterol Motil. 2023-2
Medicine (Baltimore). 2022-9-2
J Gastroenterol. 2022-2
Front Pharmacol. 2021-8-27
Pediatric Health Med Ther. 2021-8-6
Front Psychiatry. 2020-8-25
J Neurogastroenterol Motil. 2020-4-30
J Neurogastroenterol Motil. 2020-1-30